| Regulatory
Matters |
| |
Benzocaine
Topical Products: Sprays, Gels and Liquids |
| |
Bisphosphonates |
| |
Buflomedil-containing
medicines |
| |
Celecoxib |
| |
Dolasetron
mesylate |
| |
Ipilimumab |
| |
Prasugrel |
| |
Rosiglitazone |
| |
Stavudine |
| |
Tigecycline |
|
Safety of Medicines |
| |
Drug-induced
hyponatraemia |
| |
Immune
Globulin Subcutaneous (Human) |
| |
Lenalidomide |
| |
Long-Acting
Beta-Agonists (LABAs) |
| |
Natalizumab |
| |
Tumor
Necrosis Factor (TNF) blockers, azathioprine and/or mercaptopurine |
| Feature |
| |
Eighth
Meeting of the WHO Advisory Committee on Safety of Medicinal Products
(ACSoMP) |